<SEC-DOCUMENT>0001104659-21-136348.txt : 20211109
<SEC-HEADER>0001104659-21-136348.hdr.sgml : 20211109
<ACCEPTANCE-DATETIME>20211109170559
ACCESSION NUMBER:		0001104659-21-136348
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20211109
DATE AS OF CHANGE:		20211109
EFFECTIVENESS DATE:		20211109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260924
		FILM NUMBER:		211393144

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>tm2132014d1_s3asr.htm
<DESCRIPTION>FORM S-3ASR
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>As filed with the Securities </B>and <B>Exchange Commission on November 9, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMICUS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="padding-left: 2.3in; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 2in; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>71-0869350</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.3in; font-size: 10pt; text-align: center">(State of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 2in; font-size: 10pt; text-align: center">(I.R.S. Employer<BR>
Identification Number)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3675 Market Street<BR>
Philadelphia, PA 19104<BR>
(215) 921-7600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone number,
including area code, of Registrant&#8217;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>John F. Crowley<BR>
Chief Executive Officer<BR>
Amicus Therapeutics, Inc.<BR>
3675 Market Street<BR>
Philadelphia, PA 19104<BR>
(215) 921-7600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approximate date of commencement of proposed
sale to the public:<BR>
From time to time after the effective date of this Registration Statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If the only securities being registered on this
Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered
only in connection with dividend or interest reinvestment plans, check the following box. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If this Form is a registration statement pursuant
to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If this Form is a post-effective amendment to
a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp;</FONT><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer&nbsp;</FONT><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 29%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Smaller
    reporting company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
    growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><BR>
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font-size: 10pt; font-weight: bold; text-align: center">CALCULATION OF REGISTRATION FEE</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Title of Each Class of Securities</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>to be Registered(1)</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Amount to be</B></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Registered(2)</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Proposed Maximum</B></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Offering Price Per</B></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Share(3)</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Proposed Maximum</B></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Aggregate Offering</B></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Price(3)</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Amount of</B></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Registration Fee</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-size: 10pt">Common Stock, $0.01 par value per share</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">11,296,660</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">12.04</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">136,011,786.40</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">12,608.29</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Common Stock, $0.01 par value per share underlying warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,349,705</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">12.04</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">100,530,496.40</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">9,319.18</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Total Registration Fee</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">21,927.47</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt; text-align: left">(1)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">All shares of common stock registered hereby are offered for the account of certain selling stockholders.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(2)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Pursuant to Rule 416 under the securities act of 1933, as amended (the &ldquo;Securities Act&rdquo;), this registration statement also covers an indeterminate number of additional shares of common stock as may be issuable with respect to the shares being registered hereunder as a result of a stock split, stock dividend, recapitalization or other similar event.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(3)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act, based upon the average of the high and low prices of the registrant&rsquo;s common stock on November 8, 2021, as reported on the NASDAQ Global Market.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMICUS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 97px; width: 291px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>19,646,365 <FONT STYLE="font-size: 10pt">Shares
of Common Stock</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus relates to the resale of up to 19,646,365 shares of
common stock, par value $0.01 per share of Amicus Therapeutics, Inc., 8,349,705 of which are underlying warrants, by the selling stockholders
identified beginning on page 9 of this prospectus, together with any additional selling stockholders identified in any applicable prospectus
supplement. The selling stockholders acquired shares of common stock or warrants to acquire shares of common stock from us, as applicable,
in connection with the Purchase Agreements (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not selling any shares of our common stock under this prospectus
and we will not receive any of the proceeds from the sale of shares by the selling stockholders. The selling stockholders may sell the
shares of common stock described in this prospectus through public or private transactions at market prices prevailing at the time of
sale or at negotiated prices. Additional information about how the selling stockholders may sell their shares of common stock is provided
in the section of this prospectus entitled &#8220;Plan of Distribution.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NASDAQ Global Market under the symbol
 &#8220;FOLD.&#8221; On November 8, 2021, the last reported sale price for our common stock on the NASDAQ Global Market was $11.93
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our common stock involves a high degree of risk. You
should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page 5 of this
prospectus and under similar headings in the other documents filed with the Securities and Exchange Commission that are incorporated by
reference in this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation
to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prospectus dated November 9, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 90%"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT
THIS PROSPECTUS</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt; width: 10%"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD>
  </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS
  SUMMARY</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK
  FACTORS</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING
  STATEMENTS</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE
  OF PROCEEDS</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING
  STOCKHOLDERS</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN
  OF DISTRIBUTION</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
  MATTERS</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS&nbsp;</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
  YOU CAN FIND MORE INFORMATION</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION
  OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are responsible for the information contained and incorporated
by reference in this prospectus, any accompanying prospectus supplement and in any related free writing prospectus we prepare or authorize.
We have not authorized anyone to provide you with any other information, and we take no responsibility for any other information that
others may provide you. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell, or a solicitation
of an offer to purchase, any securities other than the registered securities to which they relate, nor do this prospectus and any accompanying
prospectus supplement constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered hereby, or thereby
in any jurisdiction to or from any person whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction.
The information appearing or incorporated by reference in this prospectus, any accompanying prospectus supplement, and any related free
writing prospectus, is accurate only as of the date thereof, regardless of the time of delivery of this prospectus, any accompanying prospectus
supplement, or any related free writing prospectus, or of any sale of our securities. Our business, financial condition, and results of
operations may have changed since those dates. It is important for you to read and consider all the information contained in this prospectus
and in any accompanying prospectus supplement, including the documents incorporated by reference herein or therein, before making your
investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS
PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of an automatic shelf registration statement
that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), as a &#8220;well-known seasoned issuer&#8221; as defined
in Rule 405 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), utilizing a &#8220;shelf&#8221; registration
process. Under this process, selling stockholders named in this prospectus or in one or more supplements to this prospectus may offer
or sell shares of our common stock, as described in this prospectus, in one or more offerings from time to time. Each time any selling
stockholder not named in this prospectus (or in any supplement to this prospectus) sells shares of common stock under the registration
statement of which this prospectus is a part, such selling stockholder must provide a copy of this prospectus and any applicable prospectus
supplement, to a potential purchaser, as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may also authorize one or more free writing prospectuses or prospectus
supplements to be provided to you in connection with these offerings. Any related free writing prospectus or prospectus supplement may
also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this
prospectus and, accordingly, to the extent inconsistent, information in this prospectus is superseded by the information in any prospectus
supplement or any related free writing prospectus and any documents incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may offer and sell shares of our common stock
directly to purchasers through agents selected by the selling stockholders, or to or through underwriters or dealers. A prospectus supplement,
if required, may described the terms of the plan of distribution and set forth the names of any agents, underwriters or dealers involved
in the sale of shares of our common stock. See &#8220;Plan of Distribution.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read this prospectus together with any applicable prospectus
supplement, as well as additional information described under the heading &#8220;Where You Can Find More Information.&#8221; You should
only rely on the information contained or incorporated by reference in this prospectus, and any applicable prospectus supplement or any
related free writing prospectus that we may authorize to be provided to you. We have not authorized, and no selling stockholder has authorized,
any other person to provide you with different or additional information. If anyone provides you with different or inconsistent information,
you should not rely on it. No offer of shares of common stock is being made in any jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should not assume that the information in this prospectus, any
applicable prospectus supplement, any related free writing prospectus or any document incorporated by reference herein or therein is accurate
as of any date other than the date on the cover of the applicable document. Our business, financial condition, results of operations and
prospects may have changed since those dates. We urge you to read carefully this prospectus, the documents incorporated by reference in
this prospectus, any applicable prospectus supplement and any applicable free writing prospectus before making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Unless the context requires otherwise, references in this prospectus
to &#8220;the Company,&#8221; &#8220;Amicus,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and other similar terms mean
Amicus Therapeutics, Inc. and our wholly owned subsidiaries.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS
SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt"><I>This summary highlights selected information contained elsewhere
or incorporated by reference into this prospectus, and does not contain all the information that you should consider before investing
in our common stock. You should carefully read the entire prospectus, including the risks of investing on our common stock discussed under
the heading &#8220;Risk Factors&#8221; on page 5 of this prospectus and under similar headings in the other documents that are incorporated
by reference herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt">We are a global, patient-dedicated biotechnology company focused on
discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio of product opportunities led by the first,
oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease that is under
review with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), and an industry leading rare disease gene therapy portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt">The cornerstone of our portfolio is Galafold&reg; (also referred to
as &#8220;migalastat&#8221;), the first and only approved oral precision medicine for people living with Fabry disease who have amenable
genetic variants. Migalastat is currently approved under the trade name Galafold&reg; in the United States (&#8220;U.S.&#8221;), European
Union, United Kingdom, and Japan, with multiple additional approvals granted and applications pending in several additional geographies
around the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt">The lead biologics program of our pipeline is Amicus Therapeutics GAA
(&#8220;AT-GAA&#8221;, also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class
treatment paradigm for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation to AT-GAA for the treatment of
late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) target action date of
May 29, 2022 for the New Drug Application (&#8220;NDA&#8221;) for miglustat and July 29, 2022 for the Biologics License Application (&#8220;BLA&#8221;)
for cipaglucosidase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt">We have established an industry leading gene therapy portfolio of potential
therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital and a&nbsp;research collaboration
with the University of Pennsylvania (&#8220;Penn&#8221;). Our pipeline includes gene therapy programs in rare, neurologic/neuromuscular
diseases lysosomal disorders (&#8220;LDs&#8221;), specifically: CLN6 Batten Disease (&#8220;CLN6&#8221;), CLN3 Batten Disease (&#8220;CLN3&#8221;),
and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder, Mucopolysaccharidosis Type IIIB (&#8220;MPSIIIB&#8221;),
as well as a next generation program in Mucopolysaccharidosis Type IIIA (&#8220;MPSIIIA&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt">In the first quarter of 2020, the FDA granted Fast Track designation
to the CLN3 gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. In September 2020 and February
2021, the European Medicines Agency granted Priority Medicines designation and the FDA granted Fast Track Designation, respectively, to
the CLN6 gene therapy, AT-GTX-501, for the treatment of patients with variant late infantile neuronal ceroid lipofuscinosis 6 (&quot;vLINCL6&quot;).
The research collaboration with Penn also provides us with exclusive disease-specific access and option rights to develop potentially
disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including
Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt">We were incorporated under the laws of the State of Delaware on February
4, 2002. Our global headquarters are located at 3675 Market Street Philadelphia, PA 19104 and our telephone number is (215) 921-7600.
Our website address is www.amicusrx.com. We make available free of charge on our website our annual, quarterly and current reports, including
amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material
to, the SEC. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information
contained on our website as part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt">Throughout this prospectus, when we refer to the shares of our common
stock, the offer and sale of which are being registered on behalf of the selling stockholders on the registration statement of which this
prospectus is a part, we are referring to the shares of common stock held by Perceptive Life Sciences Master Fund, Ltd. (the &#8220;Perceptive
PIPE Investor&#8221;<I>)</I>, pursuant to the Securities Purchase Agreement, dated September 29, 2021, by and between the Company and
the Perceptive PIPE Investor (the &#8220;Perceptive Purchase Agreement&#8221;); the shares of common stock held by certain third party
purchasers (the &#8220;Third Party Purchasers&#8221;), pursuant to the Securities Purchase Agreement, dated September 29, 2021, by and
between the Company and the purchasers set forth on Schedule A&nbsp;attached thereto (the &#8220;Third Party Purchase Agreement&#8221;);
and the shares of common stock underlying warrants to purchase common stock held by certain entities affiliated with Redmile Group LLC
(the &#8220;Redmile Purchasers,&#8221; and collectively with the Perceptive PIPE Investor and the Third Party Purchasers, the &#8220;Purchasers&#8221;),
pursuant to the Securities Purchase Agreement, dated September 29, 2021, by and between the Company and the Redmile Purchasers (the &#8220;Redmile
Purchase Agreement,&#8221; and collectively with the Perceptive Purchase Agreement and the Third Party Purchase Agreement, the &#8220;Purchase
Agreements&#8221;). When we refer to the &#8220;selling stockholders&#8221; in this prospectus, we are referring to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>The
Offering </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" ALIGN="CENTER" STYLE="width: 90%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"><B>Common Stock Offered by the Selling Stockholders</B></TD>
  <TD STYLE="width: 50%">19,646,365 shares, including 8,349,705 shares underlying warrants to purchase common stock.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B>Use of Proceeds</B></TD>
  <TD>All shares of common stock offered hereby are being sold by the selling stockholders. Accordingly, we will not receive any proceeds from
the sale of these shares.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B>Risk Factors</B></TD>
  <TD>An investment in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under
 &#8220;Risk Factors&#8221; on page 5 of this prospectus and under similar headings in the other documents that are incorporated by
reference herein, as well as the other information included in or incorporated by reference in this prospectus.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B>NASDAQ Global Market Symbol</B></TD>
  <TD>Our common stock is quoted and traded on the NASDAQ Global Market under the symbol &#8220;FOLD.&#8221;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -3.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -3.25in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing in our common stock involves risks. Prior to making a decision
about investing in our securities, you should carefully consider the specific factors discussed below and any factors discussed under
the heading &#8220;Risk Factors&#8221; in any prospectus supplement, together with all of the other information contained or incorporated
by reference in this prospectus or any prospectus supplement. You should also consider the risks, uncertainties and assumptions discussed
under the heading &#8220;Risk Factors&#8221; in our <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887921000004/fold-20201231.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed on March 1, 2021</A>, with the SEC, and our quarterly report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001178879/000117887921000013/fold-20210930.htm" STYLE="-sec-extract: exhibit">Form 10-Q for the period ended September 30, 2021, filed on November 9, 2021</A>, with
the SEC, each of which is incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other
reports we file with the SEC in the future. The risks and uncertainties we have described therein and below are not the only risks that
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_014"></A>FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and the documents incorporated by reference herein
contain, and any prospectus supplement and the documents incorporated by reference therein may contain, forward-looking statements that
involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts,
that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues,
projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by, or include the words
 &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
 &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;outlook,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221;
 &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; the negatives
or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying
words.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have based these forward-looking statements on our current expectations
and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are
reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following
important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed
or implied in our forward-looking statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the scope, progress, results and costs of our clinical trials of our drug candidates and gene therapy candidates, including but not
limited to AT-GAA, CLN6 and CLN3;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing our Enzyme Replacement
Therapy (&#8220;ERT&#8221; or &#8220;ATB200&#8221; or &#8220;cipaglucosidase alfa&#8221;) for the treatment of Pompe disease and gene
therapies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the future results of on-going preclinical research and subsequent clinical trials for cyclin-dependent kinase-like 5 (&#8220;CDKL5&#8221;)
deficiency disorder, Pompe gene therapy, Fabry gene therapy, MPSIIIB, MPSIIIA and other pipeline candidates we may identify from time
to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such
therapies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any changes in regulatory standards relating to the review of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number and development requirements of other product candidates that we pursue;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to realize the expected benefits of our business combination agreement for our gene therapy business, which could result
in additional unanticipated costs and risks;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs of commercialization activities, including product marketing, sales, and distribution;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the emergence of competing technologies and other adverse market developments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to successfully commercialize Galafold&reg; (also referred to as &#8220;migalastat HCl&#8221;) and, if our regulatory
filings are accepted and approved, AT-GAA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to manufacture or supply sufficient clinical or commercial products, including Galafold&reg;, AT-GAA and our gene therapy
candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to obtain reimbursement for Galafold&reg; and, if our regulatory filings are accepted and approved, AT-GAA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold&reg;;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to obtain market acceptance of Galafold&reg; and, if our regulatory filings are accepted and approved, AT-GAA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related
claims;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which we acquire or invest in businesses, products, and technologies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the
expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to establish collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments
from any such collaborators;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to adjust to changes in the European and United Kingdom markets in the wake of the United Kingdom leaving the European
Union;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which our business could be adversely impacted by the effects of the novel coronavirus (&#8220;COVID-19&#8221;) outbreak,
including due to actions by us, governments, our customers or suppliers or other third parties to control the spread of COVID-19, or by
other health epidemics or pandemics;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fluctuations in foreign currency exchange rates; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in accounting standards.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In light of these risks and uncertainties, we may not actually achieve
the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking
statements we make. We have included important factors in the cautionary statements included in this prospectus, particularly those incorporated
by reference in the section captioned &#8220;Risk Factors&#8221; that we believe could cause actual results or events to differ materially
from the forward-looking statements that we make. Those factors and the other risk factors described therein are not necessarily all of
the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking
statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential
impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations, or investments we may make. Consequently, there
can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they
will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance
on such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read this prospectus and the documents that we
incorporate by reference herein completely and with the understanding that our actual future results may be materially different
from what we expect. These forward-looking statements speak only, as applicable, as of the date of this prospectus, any prospectus
supplement or the documents incorporated by reference therein. We undertake no obligation, and specifically decline any obligation,
to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected
results expressed or implied in such statements will not be realized, except as may be required by law. Before deciding to purchase
our securities, you should carefully consider the risk factors discussed and incorporated by reference in this prospectus and in the
registration statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders will make offers and sales pursuant to this
prospectus and any applicable prospectus supplement. We will not receive any proceeds from the sale or other disposition by the selling
stockholders of the shares of our common stock covered hereby, or interests therein. The selling stockholders will pay any expenses incurred
for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of these shares.
We will bear all other costs, fees and expenses incurred in effecting the registration statement of which this prospectus forms a part,
including, without limitation, all registration fees, listing fees of the NASDAQ Global Market and fees and expenses of our counsel and
our accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_006"></A>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are registering for resale an aggregate of 19,646,365 shares of
our common stock, including 8,349,705 shares of common stock that may be acquired upon exercise of warrants, that may be sold by the selling
stockholders set forth herein. The shares of common stock registered hereby, including those underlying warrants, were issued pursuant
to the Purchase Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Section 6.1 of each of the Purchase Agreements, we
agreed to file with the SEC, a registration statement to register for resale the shares of our common stock, including those
underlying warrants, that we issued pursuant to such Purchase Agreements. Pursuant to Section 6.3 of each of the Purchase
Agreements, we agreed to use commercially reasonable efforts to keep such registration statement effective until the earlier of (i)
the date on which all such shares of common stock, including those underlying warrants, have been sold pursuant to such registration
statement and (ii) at such time as all such shares of common stock, including those underlying warrants, can be freely sold without
volume limitations pursuant to Rule 144 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficial ownership is determined in accordance with the rules of
the SEC, and includes voting or investment power with respect to our common stock. Except as indicated by the footnotes below, we believe,
based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect
to all shares of common stock that they beneficially own, subject to applicable community property laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may sell some, all or none of their respective
shares of common stock offered by this prospectus from time to time. We do not know how long the selling stockholders will hold their
respective shares of common stock covered hereby before selling them. The table below is based on 278,645,807 shares of common stock outstanding
as of November 1, 2021 and assumes the selling stockholders dispose of all of the shares of common stock covered by this prospectus and do not acquire beneficial
ownership of any additional shares. The registration of these shares does not necessarily mean that the selling stockholders will sell
all or any portion of the shares covered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares Beneficially</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Owned Prior to</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the Offering</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of<BR>
Shares Being<BR>
Registered for</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares Beneficially</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Owned After the</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name of Selling Stockholder</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares(8)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Percentage(9)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Resale(10)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares(11)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Percentage(9)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left">ENTITIES AFFILIATED WITH REDMILE GROUP, LLC (1)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">28,375,254</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">9.99</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,349,705</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">22,984,483</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">8.25</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: left">Perceptive Life Sciences Master Fund, Ltd (2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26,559,443</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.53</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,438,114</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,121,329</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">RIA, AVORO CAPITAL ADVISORS LLC (3)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,404,273</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,929,273</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,475,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">INVUS PUBLIC EQUITIES, L.P. (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,946,955</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,053,045</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED (5)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">982,873</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">491,159</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">491,714</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">SPHERA BIOTECH MASTER FUND LP (6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">211,198</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">211,198</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">SPHERA GLOBAL HEALTHCARE MASTER FUND (7)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">279,961</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">279,961</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Represents less than 1% of the total aggregate amount of shares of our common stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">The shares registered for resale consist of common shares underlying
(i) a warrant to purchase 6,623,305 shares of common stock held by RedCo II Master Fund, L.P. (&#8220;RedCo II&#8221;), (ii) a warrant
to purchase 506,300 shares of common stock held by Redmile Capital Fund, LP (&#8220;Redmile Capital&#8221;) and (iii) a warrant to purchase
1,220,100 shares of common stock held by Redmile Capital Offshore Fund (ERISA), Ltd. (together with RedCo II and Redmile Capital, the
 &#8220;Selling Redmile Funds&#8221;). The remaining shares listed under &#8220;Shares Beneficially Owned Prior to the Offering&#8221;
and &#8220;Shares Beneficially Owned After the Offering&#8221; consist of 22,984,483 shares of common stock held by the Selling Redmile
Funds and certain other private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC. <FONT STYLE="background-color: white">The
warrants described above may not be exercised if, upon giving effect to such exercise, the aggregate number of shares of common stock
(or the combined voting power) beneficially owned by the holder together with such holder&#8217;s affiliates, any person having beneficial
ownership of shares of common stock owned by the holder as calculated in accordance with Section 13(d) of the Exchange Act, or any persons
acting as a Section 13(d) group together with such holder or any of such holder&#8217;s affiliates would exceed 9.99% of the number of
shares of common stock outstanding immediately after giving effect to the exercise (the &#8220;Beneficial Ownership Limitation&#8221;).
However, any holder may increase or decrease such percentage, but not in excess of 19.99%, upon at least 61 days&#8217; prior notice
from the holder to the Company. The &#8220;Shares Beneficially Owned Prior to the Offering&#8221; excludes an aggregate of 2,958,934
shares of common stock issuable upon the exercise of the warrants described above, which would not be exercisable within 60 days of November
1, 2021 by virtue of the Beneficial Ownership Limitation described above.&nbsp;</FONT>Redmile Group, LLC is the investment manager/adviser
to each of the private investment vehicles described herein (collectively, the &#8220;Redmile Funds&#8221;) and, in such capacity, exercises
voting and investment power over all of the securities held by the Redmile Funds and may be deemed to be the beneficial owner of these
securities. Jeremy C. Green serves as the managing member of Redmile Group, LLC and also may be deemed to be the beneficial owner of
these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his
pecuniary interest in such shares, if any. The address of the Redmile Funds is c/o Redmile Group, LLC One Letterman Drive, Building D,
Suite D3-300, San Francisco, California 94129.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">Perceptive Advisors LLC shares voting power and investment power
in the shares hereby registered with Perceptive Life Sciences Master Fund, Ltd.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: left">The shares reported under &#8220;Shares Beneficially Owned Prior
to the Offering&#8221; consist of shares in the Avoro Life Sciences Fund LLC and a separately managed account, both managed by the investment
advisor, Avoro Capital Advisors LLC (&#8220;Avoro Capital Advisors&#8221;). Avoro Capital Advisors maintains sole voting and investment
power. Shares being registered for resale are held by Avoro Life Sciences Fund LLC.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: left">Invus Public Equities, L.P. (&#8220;Invus PE&#8221;) directly
holds 6,000,000 shares. Invus Public Equities Advisors, LLC (&#8220;Invus PE Advisors&#8221;) controls Invus PE, as its general partner
and accordingly, may be deemed to beneficially own the shares held by Invus PE. Artal Treasury Limited (&#8220;Artal Treasury&#8221;)
controls Invus PE Advisors, as its managing member and accordingly, may be deemed to beneficially own the shares that Invus PE Advisors
may be deemed to beneficially own. Artal International S.C.A. (&#8220;Artal International&#8221;) through its Geneva branch, is the sole
stockholder of Artal Treasury and may be deemed to beneficially own the shares that Artal Treasury may be deemed to beneficially own.
Artal International Management S.A. (&#8220;Artal International Management&#8221;), as the managing partner of Artal International, controls
Artal International and accordingly, may be deemed to beneficially own the shares that Artal International may be deemed to beneficially
own. Artal Group S.A. (&#8220;Artal Group&#8221;), as the sole stockholder of Artal International Management, controls Artal International
Management and accordingly, may be deemed to beneficially own the Shares that Artal International Management may be deemed to beneficially
own. Westend S.A. (&#8220;Westend&#8221;), as the parent company of Artal Group, controls Artal Group and accordingly, may be deemed
to beneficially own the shares that Artal Group may be deemed to beneficially own. Stichting Administratiekantoor Westend (the &#8220;Stichting&#8221;),
as majority shareholder of Westend, controls Westend and accordingly, may be deemed to beneficially own the Shares that Westend may be
deemed to beneficially own. As of the date of this prospectus Mr. Amaury Wittouck, as the sole member of the board of the Stichting,
controls the Stichting and accordingly, may be deemed to beneficially own the Shares that the Stichting may be deemed to beneficially
own.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: left">Based on information provided to the Company by the Selling
Stockholder, such shares may be deemed to be beneficially owned by Janus Capital Management LLC (&#8220;Janus&#8221;), an investment
adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for the Fund and has the ability to make
decisions with respect to the voting and disposition of the shares subject to the oversight of the board of directors of the Fund. Under
the terms of its management contract with the Fund, Janus has overall responsibility for directing the investments of the Fund in accordance
with the Fund&#8217;s investment objective, policies and limitations. The Fund has one or more portfolio managers appointed by and serving
at the pleasure of Janus who makes decisions with respect to the disposition of the shares. The address for Janus is 151 Detroit Street,
Denver, CO 80206.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Sphera Biotech Master Fund LP
owns sole voting power and investment power in the shares hereby registered</FONT>.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Sphera Global Healthcare Master
Fund owns sole voting power and investment power in the shares hereby registered</FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(8)</TD><TD STYLE="text-align: left">With respect to the Entities affiliated with Redmile Group,
LLC, this column represents both shares of common stock and shares underlying warrants to purchase common stock. With respect to all
other selling stockholders, this column represents only shares of common stock.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(9)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on 278,645,807 shares outstanding
as of November 1, 2021.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(10)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Represents the number of shares
being registered on behalf of the selling stockholder pursuant to the registration statement, of which this prospectus forms a part,
which may be less than the total number of shares beneficially owned by such selling stockholder.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(11)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Assumes the selling stockholders
dispose of all of the shares of common stock covered by this prospectus and do not acquire beneficial ownership of any additional shares.
The registration of these shares does not necessarily mean that the selling stockholders will sell all or any portion of the shares covered
by this prospectus.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: a4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_007"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders and any of their pledgees, assignees and successors-in-interest
may, from time to time in one or more transactions on NASDAQ or any other organized market where our shares of common stock may be traded,
sell any or all of their shares of our common stock offered hereby through underwriters, dealers or agents, directly to one or more purchasers
or through a combination of any such methods of sale. The selling stockholders may distribute the shares of our common stock offered hereby
from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at a fixed price or prices, which may be changed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at market prices prevailing at the time of sale;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at prices related to such prevailing market prices; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at negotiated prices.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may use any one or more of the following methods
when selling the shares offered hereby:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the over-the-counter market;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in transactions otherwise than on these exchanges or systems or in the over-the-counter market;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through the writing or settlement of options, whether such options are listed on an options exchange or otherwise;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>one or more block trades in which the broker-dealer will attempt to sell the shares as agent or principal of all such shares held
by the selling stockholder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>privately negotiated transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>short sales;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>agreements between broker-dealers and the selling stockholder to sell a specified number of such shares at a stipulated price per
share; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other method or combination of methods of sale permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may also sell shares pursuant to Rule 144
under the Securities Act, if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the selling stockholders effect such transactions by selling
shares of common stock offered hereby to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or
agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions
from purchasers of the shares of common stock offered hereby for whom they may act as agent or to whom they may sell as principal
(which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those
customary in the types of transactions involved). In connection with sales of the shares of common stock offered hereby or
otherwise, the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales
of the shares of common stock offered hereby in the course of hedging in positions they assume. The selling stockholders may also
sell shares of common stock offered hereby short and deliver shares of common stock covered by this prospectus to close out short
positions and to return borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge shares
of common stock offered hereby to broker-dealers that in turn may sell such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may from time to time pledge or grant a security
interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations,
the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus or any amendment
to this prospectus under Rule 424(b)(3), or other applicable provision of the Securities Act, supplementing or amending, if necessary,
the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this
prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees,
pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders and any broker-dealer participating in the
distribution of the shares of common stock offered hereby may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities
Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale
of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Any
such discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by a selling
stockholder. The selling stockholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving
sales of the shares if liabilities are imposed on that person under the Securities Act. At the time a particular offering of the shares
of common stock offered hereby is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount
of shares of common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any
discounts, commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions or concessions
allowed or reallowed or paid to broker-dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the securities laws of some states, the shares of common stock
offered hereby may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares
of common stock offered hereby may not be sold unless such shares have been registered or qualified for sale in such state or an exemption
from registration or qualification is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that any selling stockholder will sell any
or all of the shares of common stock registered pursuant to the registration statement, of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders and any other person participating in such
distribution will be subject to the applicable provisions of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;),
and the rules and regulations promulgated thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit
the timing of purchases and sales of any of the shares of common stock offered hereby by the selling stockholders and any other participating
person. Regulation M may also restrict the ability of any person engaged in the distribution of the shares of common stock offered hereby
to engage in market-making activities with respect to the shares of common stock offered hereby. All of the foregoing may affect the marketability
of the shares of common stock offered hereby and the ability of any person or entity to engage in market-making activities with respect
to the shares of common stock offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Once sold under the shelf registration statement, of which this prospectus
forms a part, the shares of common stock will be freely tradable in the hands of persons other than our affiliates.<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_008"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the shares of common stock offered by this prospectus
has been passed upon for Amicus by Troutman Pepper Hamilton Sanders LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_009"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ernst &amp; Young LLP, independent registered public accounting firm,
has audited our consolidated financial statements included in our <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887921000004/fold-20201231.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K for the year ended December 31, 2020</A>, and
the effectiveness of our internal control over financial reporting as of December 31, 2020, as set forth in their reports, which are incorporated
by reference in this prospectus and elsewhere in this registration statement. Our consolidated financial statements are incorporated by
reference in reliance on Ernst &amp; Young LLP&#8217;s reports, given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><A NAME="a_010"></A>WHERE YOU CAN FIND
MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of the registration statement on Form S-3 we
filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever
a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you
should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated
herein by reference for a copy of such contract, agreement or other document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We file annual, quarterly and current reports, proxy statements and
other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC's website
at www.sec.gov. We also maintain a website at amicusrx.com, at which you may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. Information contained on, or that can be accessed through,
our website is not incorporated by reference into this prospectus, and you should not consider such information contained on, or accessed
through, our website as part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, you may request copies of these filings at no cost, by
writing or telephoning us at the following address or telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">Office of
the Corporate Secretary<BR>
Amicus Therapeutics,&nbsp;Inc.<BR>
3675 Market Street<BR>
Philadelphia, PA 19104<BR>
(215) 921-7600</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_011"></A>INCORPORATION OF
CERTAIN INFORMATION BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC allows us to &#8220;incorporate by reference&#8221; information
into this prospectus. This means that we can disclose important information to you by referring you to other documents we have filed separately
with the SEC, without actually including the specific information in this prospectus. The information incorporated by reference is considered
to be part of this prospectus, and information that we file later with the SEC (and that is deemed to be &#8220;filed&#8221; with the
SEC) will automatically update, and may supersede, information in this prospectus. We incorporate by reference into this prospectus and
the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC
(Commission File No. 001-33497):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887921000004/fold-20201231.htm" STYLE="-sec-extract: exhibit">Our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021;</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000114036121014545/nc10021408x1_def14a.htm" STYLE="-sec-extract: exhibit">The information specifically incorporated by reference into our Annual Report on Form 10-K from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 27, 2021;</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021, June 30, 2021 and September 30, 2021, filed with the SEC
on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887921000006/fold-20210331.htm" STYLE="-sec-extract: exhibit">May 10, 2021</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887921000008/fold-20210630.htm" STYLE="-sec-extract: exhibit">August 5, 2021</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001178879/000117887921000013/fold-20210930.htm" STYLE="-sec-extract: exhibit">November 9, 2021</A>, respectively;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Current Reports on Form 8-K, as filed with the SEC on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921002681/tm212263d1_8k.htm" STYLE="-sec-extract: exhibit">January 11, 2021</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921013630/tm215748d1_8k.htm" STYLE="-sec-extract: exhibit">February 8, 2021</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921020661/tm216326d1_8k.htm" STYLE="-sec-extract: exhibit">February 11, 2021</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921059581/tm2114909d1_8k.htm" STYLE="-sec-extract: exhibit">May 3, 2021</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921077960/tm2119052d1_8k.htm" STYLE="-sec-extract: exhibit">June 8, 2021</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921080496/tm2119601d1_8k.htm" STYLE="-sec-extract: exhibit">June 14, 2021</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921098517/tm2123815d1_8k.htm" STYLE="-sec-extract: exhibit">August 2, 2021</A> and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_8k.htm" STYLE="-sec-extract: exhibit">September 29, 2021</A>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000095012307007844/y32191ae8va12b.htm" STYLE="-sec-extract: exhibit">The description of our common stock contained in our registration statement on Form 8-A (File No. 001-33497) filed on May 23, 2007, under the Exchange Act, including any amendment or report filed for the purpose of updating such description.</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also incorporate by reference any future filings (except as specifically
enumerated above, other than any filings or portions of such reports that are not deemed &#8220;filed&#8221; under the Exchange Act in
accordance with the Exchange Act and applicable SEC rules, including current reports furnished under Item 2.02 or Item 7.01 of Form 8-K
and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the
SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the
registration statement of which this prospectus forms a part, until the selling stockholders identified herein sell all of the common
stock covered by this prospectus and will become a part of this prospectus from the date that such documents are filed with the SEC. Information
in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings
will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated
or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To obtain copies of these filings, see &#8220;Where You Can Find More
Information&#8221; on page 15 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>19,646,365 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 13.5pt"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 97px; width: 291px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>November 9, 2021</B></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant will pay all reasonable expenses incident to the registration
of the shares other than any commissions and discounts of underwriters, dealers or agents. Such expenses are set forth in the following
table. All of the amounts shown are estimates except the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>to be Paid </B></P>

</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">SEC registration fee</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">21,927.47</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left">Printing fees and expenses</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: right">15,000</TD>
    <TD STYLE="width: 1%"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Legal fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">25,000</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accounting fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">$</TD>
    <TD STYLE="font-size: 10pt; text-align: right">20,000</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Miscellaneous fees and expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,000</TD>
    <TD STYLE="padding-bottom: 1pt"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">91,927.47</TD>
    <TD STYLE="padding-bottom: 2.5pt"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 102 of the Delaware General Corporation Law permits a corporation
to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach
of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in
intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of
Delaware corporate law or obtained an improper personal benefit. The Registrant's restated certificate of incorporation provides that
no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty
as director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation
Law prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 145 of the Delaware General Corporation Law provides that a
corporation has the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that the person
is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including
attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an
action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted
in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in
any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions
brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which
such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery
or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case,
such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court
shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant's restated certificate of incorporation provides
that the Registrant will, to the fullest extent permitted by Section 145 of the Delaware General Corporation Law and the
Registrant's by-laws (each as amended from time to time), indemnify each person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative,
by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the Registrant, or is or was
serving, or has agreed to serve, at the request of the Registrant, as a director, officer, partner, or trustee of, or in a similar
capacity with, another corporation, partnership, joint venture, trust or other enterprise, including any employee benefit plan (all
such persons being referred to hereafter as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or
omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually
and reasonably incurred by, or on behalf of, the Indemnitee in connection with such action, suit or proceeding and any appeal
therefrom. Such indemnification may include payment by the Registrant of expenses in defending an action or proceeding in advance of
the final disposition of such action or proceeding upon receipt of an undertaking by the Indemnitee (such undertaking acceptable by
the Registrant without reference to the financial ability of the Indemnitee) to repay such payment if it is ultimately determined
that the Indemnitee is not entitled to indemnification under the Registrant's restated certificate of incorporation; however, the
Registrant will not indemnify any person seeking indemnification in connection with a proceeding (or part thereof) initiated by such
person, unless such initiation was approved by the Registrant's board of directors. Also, the indemnification rights provided in the
Registrant's restated certificate of incorporation (i) are not exclusive of any other rights to which those indemnified may be
entitled under any law, agreement or vote of stockholders or disinterested directors or otherwise, and (ii) will inure to the
benefit of the heirs, executors and administrators of such persons. The Registrant may, to the extent authorized from time to time
by its board of directors, grant indemnification rights to other employees of the Registrant or other persons serving the Registrant
and such rights may be equivalent to, or greater or less than, those set forth in the Registrant's restated certificate of
incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant has entered into indemnification agreements with each
of its directors. These agreements, among other things, require the Registrant to indemnify each director to the fullest extent permitted
by Delaware law, including indemnification of expenses such as attorneys' fees, judgments, fines and settlement amounts incurred by the
director in any action or proceeding, including any action or proceeding by or in right of the Registrant, arising out of the person's
services as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant maintains a general liability insurance policy that
covers certain liabilities of the Registrant's directors and officers arising out of claims based on acts or omissions in their capacities
as directors or officers. In any underwriting agreement that the Registrant enters into in connection with the sale of common stock being
registered hereby, the underwriters will agree to indemnify, under certain conditions, the Registrant, its directors, its officers and
persons who control the Registrant within the meaning of the Securities Act, against certain liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 16. EXHIBITS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 2%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 88%">&nbsp; <FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm" STYLE="-sec-extract: exhibit">&nbsp;Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant's Annual Report
on Form 10-K filed with the SEC on February 28, 2012)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.2</FONT> </A></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant's
Current Report on Form 8-K filed with the SEC on June 10, 2015)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.3</FONT></A></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant's
Current Report on Form 8-K filed with the SEC on June 8, 2018)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv3w4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.4</FONT></A></TD>
  <TD STYLE="width: 2%"> &nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv3w4.htm" STYLE="-sec-extract: exhibit">Restated By-laws of the of the Registrant (incorporated by reference to Exhibit 3.4 of the Registrant's Registration Statement on Form
S-1/A (Registration No. 333-141700), as amended, originally filed with the SEC on April 27, 2007)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-3.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated September 29, 2021, by and between Amicus Therapeutics, Inc. and Redmile Group LLC (incorporated
by reference to Exhibit 10.3 of the Registrant's Current Report on Form 8-K filed with the SEC on September 29, 2021)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.2</FONT></A></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-4.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated September 29, 2021, by and between Amicus Therapeutics, Inc. and Perceptive Life Sciences
Master Fund, Ltd. (incorporated by reference to Exhibit 10.4 of the Registrant's Current Report on Form 8-K filed with the SEC on September
29, 2021)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.3</FONT></A></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-5.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated September 29, 2021, by and among Amicus Therapeutics, Inc. and the Purchasers identified
on the signature pages thereto (incorporated by reference to Exhibit 10.5 of the Registrant's Current Report on Form 8-K filed with the
SEC on September 29, 2021)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.4</FONT></A></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex4-1.htm" STYLE="-sec-extract: exhibit">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 8-K filed
with the SEC on September 29, 2021)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000095012307007596/y32191a2exv4w1.txt" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.5</FONT></A></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000095012307007596/y32191a2exv4w1.txt" STYLE="-sec-extract: exhibit">Specimen Stock Certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s
Registration Statement on Form S-1/A (Registration No. 333-141700), as amended, originally filed with the SEC on May 17, 2007)</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 12%; text-align: left"><A HREF="tm2132014d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">5.1</FONT>*</A></TD><TD STYLE="text-align: justify; width: 88%"><A HREF="tm2132014d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Opinion of Troutman Pepper Hamilton
Sanders LLP</FONT></A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 12%; text-align: left"><A HREF="tm2132014d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.1</FONT>*</A></TD><TD STYLE="text-align: justify; width: 88%"><A HREF="tm2132014d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of Ernst &amp; Young LLP,
Independent Registered Public Accounting Firm</FONT></A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 12%; text-align: left"><A HREF="tm2132014d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.2</FONT>*</A></TD><TD STYLE="text-align: justify; width: 88%"><A HREF="tm2132014d1_ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of Troutman Pepper Hamilton Sanders LLP (included in
Exhibit 5.1 to this Registration Statement)</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 12%; text-align: left"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">24.1</FONT>*</A></TD><TD STYLE="text-align: justify; width: 88%"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Power of Attorney (included on
the signature page hereto)</FONT></A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp; &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">* Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 17. UNDERTAKINGS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(1) to file, during any period in which offers or sales
are being made, a post-effective amendment to this registration statement: (i) to include any prospectus required by Section
10(a)(3) of the Securities Act; (ii) to reflect in the prospectus any facts or events arising after the effective date of the
registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more
than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in
the effective registration statement; and (iii) to include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in the registration statement; <I>provided,
however</I>, that paragraphs (i), (ii) and (iii) do not apply if the registration statement is on Form S-3 and the information
required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC
by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(2) that, for the purpose of determining any liability under
the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(3) to remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the termination of the offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(4) that, for the purpose of determining liability under
the Securities Act to any purchaser: (A) each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part
of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and (B)
each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule
430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by
Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the
date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering
described in prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement
to which the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering
thereof; <I>provided, however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement
or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement
that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) The undersigned registrant hereby undertakes that, for purposes
of determining any liability under the Securities Act, each filing of registrant&#8217;s annual report pursuant to Section 13(a) or Section
15(d) of the Exchange Act that is incorporated by reference in this registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described under Item
15 above, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933, as amended,
the registrant, Amicus Therapeutics, Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in the city of Philadelphia, Commonwealth of Pennsylvania, on the 9th day of November, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp; </TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"><FONT STYLE="font-size: 10pt"><B>Amicus Therapeutics, Inc.</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">/s/ John F. Crowley&#9;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 46%">John F. Crowley</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 46%"><I>Chairman and Chief Executive Officer</I></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We, the undersigned officers and directors of Amicus Therapeutics,
Inc., hereby severally constitute and appoint John F. Crowley and Daphne Quimi, and all or any one of them, our true and lawful attorneys-in-fact
and agents, with full power of substitution and re-substitution in for him and in his name, place and stead, and in any and all capacities,
to sign any and all amendments (including post-effective amendments) to this registration statement, and any subsequent registration statements
pursuant to Rule 462 of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises,
as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact
or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933, as amended,
this registration statement has been signed by the following persons in the capacities and on the dates indicated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 31%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John F. Crowley</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD ROWSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chairman and Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Principal Executive Officer)</P></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U>John F. Crowley</FONT></TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Daphne Quimi&#9;</P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD ROWSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Principal Financial Officer and Principal Accounting
    Officer)</P></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daphne Quimi</FONT></TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Eiry Roberts</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Eiry Roberts</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Robert Essner</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Robert Essner</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Lynn D. Bleil</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Lynn D. Bleil</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Margaret G. McGlynn </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Margaret G. McGlynn </TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Michael G. Raab</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Michael G. Raab</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Glenn P. Sblendorio</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Glenn P. Sblendorio</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Craig A. Wheeler</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Craig A. Wheeler</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Bradley L. Campbell</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Bradley L. Campbell</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Michael A. Kelly</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Michael A. Kelly</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Burke W. Whitman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Burke W. Whitman</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2132014d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 8pt; width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Troutman Pepper Hamilton Sanders LLP<BR>
 &nbsp;400 Berwyn Park, 899 Cassatt Road <BR>
Berwyn, PA 19312-1183 <BR>
<BR>
troutman.com </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right; width: 50%; font-size: 10pt"><IMG SRC="tm2132014d1_ex5-1img002.jpg" ALT="">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">November 9, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amicus Therapeutics, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3675 Market Street</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philadelphia, PA 19104</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-size: 10pt">Re:</TD>
    <TD STYLE="font-size: 10pt">Securities Registered under Registration Statement on Form S-3</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">We have acted as counsel to
Amicus Therapeutics, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in connection with the Company&#8217;s registration
statement on Form S-3 (the &#8220;<B><I>Registration Statement</I></B>&#8221;), including the prospectus that is part of the Registration
Statement (the &#8220;<B><I>Prospectus</I></B>&#8221;<I>),</I> filed on the date hereof, with the U.S. Securities and Exchange Commission
(the &#8220;<B><I>Commission</I></B>&#8221;), under the Securities Act of 1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;).
The Registration Statement relates to the registration for resale by the selling stockholders named in the Registration Statement (the
 &#8220;<B><I>Selling Stockholders</I></B>&#8221;) of up to an aggregate of 19,646,365 shares of the Company&#8217;s common stock, par
value $0.01 per share (the &#8220;<B><I>Common Stock</I></B>&#8221;), consisting of (i) 11,296,660 shares of Common Stock issued to the
Selling Stockholders on September 29, 2021 (the &#8220;<B><I>Shares of Common Stock</I></B>&#8221;) and (ii) 8,349,705 shares of Common
Stock issuable upon the exercise of outstanding warrants (the &#8220;<B><I>Warrants</I></B>&#8221;) to purchase Common Stock (the &#8220;<B><I>Warrant
Shares</I></B>&#8221; and together with the Shares of Common Stock, the &#8220;<B><I>Shares</I></B>&#8221;), which Shares may be sold
from time to time by the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">We have reviewed the corporate
proceedings taken by the Company with respect to the registration of the Shares. We have also examined and relied upon originals or copies
of such corporate records, documents, agreements or other instruments of the Company, and such certificates and records of public officials,
and such other papers, as we have deemed necessary or appropriate in connection herewith, including, but not limited to, the Company&#8217;s
Restated Certificate of Incorporation, as amended, the Company&#8217;s Amended and Restated By-laws, the Warrants and the agreements pursuant
to which the Shares of Common Stock and Warrants, as applicable, were purchased by the Selling Stockholders. As to all matters of fact
(including, without limitation, factual conclusions and characterizations and descriptions of purpose, intention or other state of mind)
we have relied entirely upon a certificate of an officer of the Company, and have assumed, without independent inquiry, the accuracy of
that certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">In rendering this opinion,
we have assumed the genuineness and authenticity of all signatures on original documents; the legal capacity of all natural persons;
the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as
certified or photocopies; the accuracy and completeness of all documents and records reviewed by us; the accuracy, completeness and
authenticity of certificates issued by any governmental official, office or agency and the absence of change in the information
contained therein from the effective date of any such certificate; and the due authorization, execution and delivery of all
documents where authorization, execution and delivery are prerequisites to the effectiveness of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2132014d1_ex5-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 73.4pt">We express no opinion herein
as to the law of any state or jurisdiction other than the laws of the State of Delaware and the internal laws of the State of New York,
including statutory provisions and all applicable provisions of the Delaware Constitution and reported judicial decisions interpreting
such laws of the State of Delaware, and the federal laws of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">Based upon the foregoing, we
are of the opinion that, as of the date hereof, (i) the Shares of Common Stock are validly issued, fully paid and non-assessable and (ii)
the Warrant Shares, when issued and delivered upon the exercise of the Warrants in accordance with their terms, will be validly issued,
fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">We assume no obligation to supplement
this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed
herein after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">We hereby consent to the filing
of this opinion as a part of the Registration Statement and to the reference of our firm under the caption &#8220;Legal Matters&#8221;
in the Prospectus. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under
Section 7 of the Securities Act or the rules and regulations of the Commission. Except as otherwise set forth herein, this opinion may
not be used, circulated, quoted or otherwise referred to for any purpose or relied upon by any other person without the express written
permission of this firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">/s/ Troutman Pepper Hamilton Sanders LLP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Troutman Pepper Hamilton Sanders LLP</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm2132014d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the reference to our firm under
the caption &quot;Experts&quot; in this Registration Statement (Form S-3) and related Prospectus of Amicus Therapeutics Inc. for the registration
for resale an aggregate of 19,646,365 shares of its common stock and to the incorporation by reference therein of our reports dated March
1, 2021, with respect to the consolidated financial statements of Amicus Therapeutics Inc., and the effectiveness of internal control
over financial reporting of Amicus Therapeutics Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2020,
filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Ernst &amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Iselin, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">November 9, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2132014d1_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2132014d1_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K +T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKDO$GQ(\.^%K[
M[#?3RR78 9XK>/<4!Z9.0!],YK$_X7=X4_YYZC_WX7_XJM%2FU=(VCAZLE=1
M=CTBBN6\*^/M'\87-Q;Z8MT'@0._G1A1@G'&":ZFHE%Q=F9SA*#Y9*S"BBBD
M28/B7Q5;>&4MS/;RS-<;M@3  VXSDG_>%;JG<H/J,UYQ\6/^81_VV_\ 9*OZ
M=;>/?MUJ;N^@^R"13* L>2F1D?=]*[WA8/#PJ)I-WW>]NQYBQDUBITG%R2M:
MRVOW.YHKSS5/%>MZGXF?1_#I2/RBR,[JI+,N=QRV0!V__75N&]\2^';.]U+Q
M!=1W,$<6V&)-O,A8 9P!Q4/!S25VKO9==319A3<FHQ;BKW=M--SN**\STH^-
M?$]J;^#5HK: N54'Y,X] JGCZT'Q!XC\)ZW;VNNW"W=I*,EEP1@G!(; .1Z'
M^N:KZC*[C&:<ETZD+,HV4Y0DHOKI;\STRBN#U'Q%JL'Q&@TJ.ZVV3/&#%Y:G
M(*@GG&?UKN9F*02,IP0I(_*N>I0E346_M*YU4<1&JYJ/V79C;JX6TM)KEP2D
M2-(P7J0!GBLOP[XB@\26DUQ;P21)')Y>)",G@'/'UKE/"VOZGKFA>(?[1N?/
M\FV_=_NU7&5?/W0/05A>$(?%4FGSG0;F**W$O[P.$Y; _O ]L5V+ I0FIM*2
M:UOIJ<#S)RG3E3BW&2>EM=';N>PT5P^L:YKGAKPG ]]-'-JL\Q7?L7;&O/0
M '@#\ZHV^F^/;JR2^75XU+H)%B+X8@C(X"[:QC@VX\TII*]EY_@=$L>E+DC"
M3=KM*VE^^IZ-17E.E^(/%WBFX%A9WD,#Q1EI)-H3/.,DX//(X J?4-4\6>#[
MRU?4K^.\MIF.5'S!@,9&2 0<&K>7S4N3F7-V_I&2S6FX^T4)<G>VGYGI]%8F
MNG6;S2[=_#TT<4KL'+R ?<*GCD'U'Y5R\T7Q$LH'N#>03+&I9D58R2!_P$?I
M6-/#\ZOSI/LWJ=-;%^SE;DDUW2T_,]#JCJR:E)8/'I;0)<OP))R<(/48!R:Y
M_0?&7V_PM>:E=Q#S[('S5CX#\9&/3/2N>TJ[\9>+1-=6FI16MO')MQ]P ]<#
M"DG (ZUI#"34I.;247UV,:F/IRC&,$Y.:NK;V_0DD\!^(YI&DEO],>1CEF:/
M))]2=E<QX]TW5?"7AJ&:6:R,\UXJ*\,*DA=C$@Y4=\?E717FM>*O!^HVJZK=
MQWMM+\Q5<$, >0"0"#S]*K_'.19O".E2I]U[L,/H8VKIJ2JIQ4N5QEU2-LG5
M*>*23FI1>JE)O==KM&SX'E)\5Z[ $B2.)F5%2-5P Y ' KOZX7P/93#Q#X@O
MF7$+7+Q*3_$=Y)Q]./SKNJX\;R^U]WLOR0L"YNC>;UO+?U84445RG8>;_%C_
M )A'_;;_ -DKT:/_ %2?[HKE?'GARZU[3K=[(*]Q;,Q$9(&\-C.">,\"JFCZ
MGXU^UV=K>Z5 +8,J2SLOS;>YX?&<>U>@XJKAH*,E>-[W=CRHS=#&5'*+M+EL
MTK^1A>#O^2D7_P!9_P#T.NE^).?^$3;'_/=,_K67X8T'5++QS>7US9O';.9M
MLA(P<MD=Z[#Q#HZZ[HEQ8%_+9P"CX^ZP.1^%:5ZL%BH3OHE$RPU"I+!5*=K-
MN1F^ ,?\(5I^/^FF?^_C5SOQ7QLTGUS-_P"R5!H][XL\+V9T[^P9+J)7+(RH
MS8SUP5R,9Y_&DDTGQ#XTURWGU6S:QLH1]UU( &>0 >23Z^U:PI^SQ+KRDN75
M[KKY&-2LZN#6&C%\]DMGT\]B/4,_\+6LMW7=!G_O@5Z=<_\ 'K+_ +A_E7"^
M,?#NJ#7[?7]'B,\J;2\8ZAEZ''<$<8%0W7B;QA>6DEK'X=EADD4H91"_RY[C
M/%95*?UB-.4&M%9W:5M3:C5^JSJQJ1>KNK)N^GD9W@'_ ) 7B?\ Z]E_]!DK
M;^%G_(#O/^OG_P!E%6O!GA6?2M%O8[\A9K]0KQKSL7! !/K\QK TS3O&/A*:
MXM["QBNX)&SD_,IQW'S @_6MJTX5W5A&2NVK7=KV1A0IU,.J%2<79*2=E=J[
MNM#1^*G_ "#-/_Z[-_Z#7;:=_P @RT_ZXI_Z"*X;Q3I^OZ_X;TQI; &^$KM+
M#",!!R!U8]L=Z[NR1H["WC<898E!'H0!7'7LL/"%]4V>AAKO%5*EFDU'='F_
MPT_Y&'4_^N1_]#JW\5O^/;2_]^3^2U+X#T/4]+UJ_FO;1X8Y(\(S$<G=FK/Q
M$T?4-7@T];"U><QLY<+CC(&.OTKK=2'U]2NK?\ X(TJG]F2ARN]WI;7XC-U/
M7M7:31_#^CR+!+-:0EI3UR5Z9[# SD<U+_PC/C2S1[B/7Q,ZJ28GF=PWMAAB
MEUKPMJX;2M8TG_C^MK>*-X3@$%5QD9X/H14AUSQZ4VG0;8Y&"=A_^+H3]U>Q
MY?.]KWN^X./OR^L*?3EY;VM9=OU.>\,_\B1XF_W$_K74_"[_ )%FY_Z_&_\
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M9XF^+&@^&]2DTWR[F]O(CMD6!1M1O[I8GK],UQNFPII?[1\UI:HL4,I?<B#
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M %%%% !1110 4444 !&1@]*CC@BBSY<2)GKM4#-244 %%%% !00",$9!HHH
M9'#%%GRXT3/7:H&:?110 R2&*;'F1H^.FY0<4^BB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2132014d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2132014d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ (L# 2(  A$! Q$!_\0
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M%HNDSZA.CO'#MRJ8R<L%'7W-.,7)J*W9,I*$7*6R+]%0VEP+NR@N54J)HUD
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M^%7$,$4*_:7^6)<#HO-=E6-6FZ<W!]"*=6%6"J0V>U]PKF_'W_(DZA_VS_\
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G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@!%35),3%]'4D%02$E#4SI;04U)0U53
M7U1(15)!4$555$E#4UU!34E#55-?5$A%4D%0155424-37U!-4U],3T=/+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( &$!(P,!(@ "$0$#$0'_Q  ?  $  @(" P$!
M"0H("P$' @,&!03_Q !'$   !@(! P($ @8&!P8'   ! @,$!08'"  )$1(3
M(0H4%3%!418B(W&!D1<R.4)AL1@9)')WH;<X>+*UMM$S-E)V@I+P_\0 '0$
M 00# 0$               4&!P@" P0) ?_$ #<1  (#  $$ @$#! $" @L
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M,8GT;?LP(LN69B9(_"ER%9*5!Z)=N>WN3V^Q%4:@+L:=@ 9KZLA$.NV?$20
M4Q[+II+R%9$3$",?(<2YC#+5[]2NN-ZKU!-T8)O'_3V:6R.5WB#$P% A6E@L
M;FPD$A2?JE;.TICYI @=O%NY3*( 8!#EYSHA;(2FR?3OPY*V1^:3N.*3S."[
M4^44*HN[6QNHV:59X['P*H+U[C]_47#Q503G<NQ<.3',*H]J375M_M*MS_\
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M7(*?0!#Y8:(Q'K,0XYX'4(F &.8I $Q2 )C 7N8Y@*0H=Q#N8QA I2AW,81
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M'K,_B?Q$^?Q/_E/CY#DRPDPU<N&/)*@QE@QXB?)!$^T1X*/S,>/S'6!_55V
MRCK!H1L)FG#13(9%J]?@&-?FP8MI(M2&V7*O5*0N8L'B:[5RI58V;=S#0';9
MTP1?-VCF1:N(]!TF:G#TO^I!O(QWNUZJTYGK,68JKE[*U8QI>Z#DF\6&]PDE
M 723+&2<RP96!X^+ 35436-:&4M!C&&11AEV+X58)=ZS/L#+/7:Y;Z[-U2WP
MT18ZM98M] 6&OSS!I*0LY#R[=1A(Q$K&/DUF<@PD6JZC1TR<HJHNDE3(G3.!
M_$<*=?NF9HIJSD9QEO!FO-1HV0UT'C)I9S/K587<"VE4_EG[:I)VZ>G&=0(_
M0.=DX_1MO&KKLEUHX519.%6JDS< [A<,XSP?E_'=[B ;>QN1:G-TYK46B,.H
M+JUZ]JQ9,;5->?9%EY#:0.:3;!^!2P ;,3<VX+RSD7,N+;V-RDLC)QYK_?SO
MFMK(I5<.PY]9*!*M:9<1*ZCEVR4$+2,23 (EQGD'V#\?\0^P_P"/\?OSGCGI
M7<(-DU%EU4T444S*K*JG*FFDF0HF.HJH<2D23*4!$RBABD* "(F  Y"G\_QU
M+W\1^?\ \S_$=>[CG4/^D#@GUOE_Z9\3?,>M\OZ'])-*];U_4]'T/2^N^?K>
MK^R]/Q\_4_4\?+VYVP@X1<I)K(*IK(K$*JBJD<JB2J9R@8BB2I!,FJ0Q1 2G
M3,8@@(" B AS<VM81ZR]#DP?GU^59K]O'CSZ^XQY\>8\^/X\_GK2JQ7?[?"]
M3?7Q[?&P#]?/\>WK,^//_'G^9B8_F)Z]W'/ %"")@ ?+Q'Q-X@)NQNP")1\0
M'L( (=P'L(=P]O<.<E.4_?Q$!\1\3=A]P,  (E$/N40 0[@( /N ]NPAS3UN
MZ\N.>'JI^9DP, G(!1.0OZQB ?OX"8I>XE WB;Q$P!Y=A[=^P]A5"&,8A3 )
MR 4QR=P\R@?R\!,0?UB@;Q-XB( !O$WB(]A['1UY\<_ADI2-AF+J3EW[*+C6
M*)W+V0D72#%BS;IAW.NZ>.E$FS9$H?UE5U4TP_$P<^&KN8<3V^23AJIDW'MF
MEU4SK)1=>NU7FY)1)/MYJIL(N5=NSID\B^1R(F*7R#N(=P[[00Y@&Q:6FM?_
M %& LR /^?WE$2(_C\_F8_'Y_CK4;T+,%L<H&,_  ;!$SF9B(@1F8DOS,1^(
MGKL?CG'D7\P_GV_F ^X#^8#[AQS5UMZYXXXX='7669\MTK V*,AYER+)EB*1
MC.HSESLS[NGZQ8N"8JO56[)-11(',D_432CHIF50JCV3=M&B7=18@#JY=J=B
M;GMAL+EC86^&43G\GVQ[.$BS.#N4JU7TBIQM3J#-4XB(L:G6&45 MS /986*
MCLW=5RJ8UH'XEG>+Y9E2=$J!.B5>1"+RCGXC!P(&)&(J@YQA0I+TQ$.T@^25
MR!*QZP%."$92W!@,@^$IJ?O/0'^E_M_^B<=L<UT$>FER4/AS8,9@Z^"ED$)Q
M$Q$C.G:7%B?Y$ZM:BT)\,*)HY_4;SG]8W4<0H.]L_CY?-HR!>0?LN7X])\3,
M3^GUS^'\^""P^TLH\A'7FFF=4Y$DDU%55#D3322(915510P$3223* F455.8
MJ::90$QU#%(4!,(!RW9TZ'>0M&M?VU.I#>M5K(.0GJ%VRW9%8!"9L4E,+,?0
M@:DNZEEG;-M$4**6-',F3-BD7ZX[L,HJJLI**%""'IS8#')^7!R-/,P6IF)%
M6<L4KA$%&DQ>' *'K,7^T**2I(?TU+,^3#S$HLXI)0I2O2B,P6QFTV-M;81!
MS:EUYRV2R)UJ]1(==N$_+)@)R?4GRK@3I0< "Q3)*33U)4%URG;QK21<D632
M>/=6S/)+53A%.G^IQ\J;=^I ?*#K,#)U$.7,PLEU@+[C?F\I RKN*0.O[#'G
M H;@K=R;[9YS?C8BK; Y4U*)GU>Q3!_R ;BCX(E4BP@AJH]A;(E+!!;Z[*13
MM!5Y98&S(D.83Q\S48@I'0#X_J"O )PKTGCV'P%%8HE$QA."@>)2Y94CJK:T
M(-U(C8/(./\  MI1:+K>=JNL,UKDKZ!?(Y&"SUTE,1[T2")B1LK'E!82BDQD
M'RX@D-"/,^]>P&8%GS(EG6Q]47)SD2J=#7<0Y3-!']1"7L29B6&;.)/9<5GC
M1BJ83>$:B3Q(7#E10ZRRCA4YU7"IS'5<*F,HX5.8>YCJKG$RJAA$>XF.<QA'
MW$>_&9'],^/KUQ+696Q7S$$ X5<(<J?Y@6',KIE,?P8Q6?'C_INC\%T]*O?[
MD.-9\TG6=E$>8->TXW*9'XC]DE)VU_B)D""PO]WB6*./VSFGU'<G4G,N]FU.
M4,;SK2T4.YY?G)6J62//ZD?/0Z3")C$)>/4$ ,HP?J1ZKAFH<I%%&QTCJ)I'
M,9,LF'0,WBUDTIOFR\ILKD4^.8W(--Q@RJ3[]$[C:DI1_6+!<7$PQ%*G0,^Z
M9KHM9YBZ3.^;MVJZ15R)N1<)%04K\B(B/<1$1'[B/N(_QX[B'V'MR<]K@>5O
M<&C@-VS?#)C-R<R;59E==^4XYTF5V0;:[Z\,8=%7S>:Y!(DR $)D2&*\GF^G
MC<S+F].M1/3F]H7XK6 >RE#-(+*W!(*>AT@ V3^/P^"B1&2DHB8G97U_K+],
M2RO",8[<7%C1<X)F ]B);:BT#U>_B!I"U5F&CRG+V_:$,Z R/W5 @"'?,/%V
MT.MV;723##V>\-Y0DEFBK\D50LE4ZU2X,D$T%'#I2(AIAW*)(-BN4/FE%69"
MMA5(5<4S#V#5'^9__K-_^P_^_/I*3<[9C>X5S(% L4M3;Q4)=E/U>VUUV>,G
MX&9CU069R,;((>*R*Z*@?K$,)V[E(RK5XBX:+KH*5YU/Z1\ T-_1>5[%>U"R
M^"-.M2N()T#/I#2JKHL!1%X@R 6& S)"#)B!F=L[^J+:%ZHUN-9;:TL#YRSW
MVZSA5)#[RH;++8$8A[2,$409>(F0B?,;<+CD3/2+ZDD-U!\ %<VAQ%1>Q&+4
MXV S-6&14F:,DLX1.2$R57H\O8$JS=2-7"BS1 OI5ZRM9B [ T0BUWDLW*5[
M^#J<9V=#!V:Q5-+,L%7LI+S(^P^"!JC\1#4/60.KN&/1R6 P)D2CJW>)M9W(
M<JCM9-@;.?H("Q7;'B)]2_!+8/F96Y)P2G*F?9;0,"_(SUT+M'GJM:O:\YAV
M MH$4A<4T2<MIF1U11&8E&;?T:[7D50 ?!U9+$YBH!F/;N+J12 .X^W*A71+
MTI-ODYWVV/V%0^N)Y7J>0\(QUCD6IW8'RGG!-:WY,NT4900\)6E(.ZL6*<)+
M =J-@712,0R/MEC\3AMH6"H^(--:U)@1_>7R>9LJH(+%(*=0J[US&8]@W_BH
M;_9YVWIRUC.DJ0@E&DQR_<4UB^6*V@?79UPTDU3QIKS!ZPY:L[VGQ\C)7JX1
M=KH#5K:;U9I)W.6JPG35457:LE7CGY")(_.1PV@(N-;K#Y-CB%E."\+YEG]G
M-'6XCE6K?)>>;%)";%=M:N_-XQC6#=]@&6GH@2OZ*&J( F?FJ,2[QX 9B .9
M<LXI?[JT<SD^G6J<?X7EVG-38"PY-_D&ND$R@@KI;,Q2I-!GL?B5V%M5'B2*
M)KCS\+?\!Y=F*^]47K64L+9(>Q:[A(5$G$'?\;6DZ!7B!C FH7Y.PPA'C8_8
M@G1!(X=@.'-H9I[L-";6ZQX3V$@022;Y0H,+8)-BB8IR0UI(D:-N=?$Q5% $
M]?MK":AS]S>7^Q@8Q2B;Q#6^]0?9+%>W6UF1-B,3T&P8SBLG(5V8LM3L<M R
M[HEW8PS>#L,TS7KZBC0C&?3C(R3535,+D9A:6<*>*;E(A+(_PQ.UGU.K9JTV
ML<D!GE5>AF[%S=PH03GKM@<,H'),.S\SE,",39?T=L2;9(I^ZELEW @4I%#<
MDO\ J&XU?Y1VQP.8V\XJ/(..JJ6-BE/QFRM6U5UZ^K7]DFP&C3TAJL Q,P"N
M-AOF((IZCSL5R&EQSN)N\3K7QN8FZVRK*MQ! I]C/8UV>^!:"S7-JB3U2,@)
M&Z4K\3(AYE-Z\4<J\Z76QC]L#\KZNO,06)@ZCG#MJY8.8W,]"*,AZS-1-5--
MHW<KJJ'$X)I!V5,)13*8**.I6PN<,1;%XSON+49[).68V2FH'$M5FIF>GF:V
M3K_5YS'5+DTX)S(*-IV0A9>V)249"O#(Q\K((-V,HNG&K.^]]SK;?V6VWO\
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M6%V!Q&DDW#=U'MI!*\EU46S=STX-TT72"+A,FN&3%RIKID5("[2OK.FJP%4
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M%&,G)E)XG+RDP1^^<*"U$#1D>BFCXI"<TN''CW>YAD<FY#1K<5<Z>)\;PLK
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M-YQO>U8J$O+)79=YXB<@#V$Q0'\A, #_ "[]^1CZ!YUW&G=4\B2>ZF'[+#;
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M&@IK6)7<3LQVZ?P#CKOU.%_KVRY=G2%1"P*JD@0U*$-"9%I(ACF-8!2N7/,
MDP6+#<<<<@_J8^G'''#HZK^=96+DW^V'1K781DD_0C]UF;A^LQCWKU%BW_27
M#IO7?*M4%DV:'BDH85G)DD@*FH;S\4SB6P#_ '3?_E_F/.1#OV^_M[^PB'\^
MP^_[A]N<\<.IOEIXG&,::L)'C=;4K#8ATG-R-/5L:DF2I6$(^&;'PP,,;\D!
M\DR$EZ0AYV*-#7Y!K18EL[S\YQ(E4!%7]/SDY\##/D*7?+"OEF9!?I)>G@O'
MM,$^J4;(H=<KJ?2*T=((QSW#.LI&D@LQ>),':B-1IQ%2-7RB)6CDZ1B'*H1N
MLH9,Q#E.!1*8 XR1&R)_B$-?Y0D=('C$NGQ=FJLF1@[-')N1O5[,5LI(%0%D
MFX$JA# W.N580.00)V.41G8[>XC[^_\ B/;^7?L'\ X[>_?W_+[CV_EW[?Q[
M=^+I<Z,K[[WZ:,2[@E;A$K^W/@0K\>IX$:/O];\D8TXM?5]8@99\/V)@?D)(
M'AX#414^^4_!S%_+OD^M'[C=L6=::'K\_P"!&;,H^S[3,P$,^&/;XXJZ]5+7
M2A8OZB>*MW=D-=G>R.E-YQ0UQ#G%K'4^4O;C$-RA%9-O5,A2U<C%A=#%>B^A
M$V3]N":9TT+1&E*$XY@F\OUWA]30/8S;?7ZE=-+IPXNN52JMTAKSGS9;(>)L
MEX_JF(H"NR<7-Q9J0JZF()R^R,FX8K.()I.LSLWLR>$391<C&$G96)MFF*4X
M"!@ 0$! 0'\0$.P@/Y@(>P@/<!#V$!#GK1;(-P$J"*:)1'R$J29$R>78 \O!
M,"E\NP 43=O(2@!>_8  %JMW2LKPZ.=8J:SK^5ANP*#JW*=+.PRJ%%@*MG1P
M*BA^[?H*LRM#5:=.LZ*]3[M2U"VP](?V[6>O=NU[F<FAI:Z]J\A_'J-W6BS$
MUBLUZ.U8;,U:=QE:#:#*-EZ9:^*EA$&'QP3=<*,DI+_5M_3HV1D/E.HS@YV\
M"/8/'PM&I"R/JNG7R:*_RS9/N'JN5A30)W[F4#DV]R)9E*?:DZ6JU0N!Z]8"
M559\5,[)&R&C'I8%5V17]D=JG+"S.X*I^S%$IP/^KW'GTXAW_/V_(1#_ "$.
M_P#'G/&/=WBN8_'<F:JPCCY:9"XF?*-O]2MJMR+$2L86*I7\<Q\C(:)3,^G\
M2[:F(-76W]3[3"G='.$E"$**K^GU"J00.@RDR;!?)$^B_CF/$0?\]47].)[I
MS4>O75MU(=:=@-@.I6.3+@6Y4/(F+\JY7MUUG!E/5KD+48HKHU.\Y%'T47[F
MU%!9P^.[>-'3JIGAB#)!T ;../<M[XZZ9$QI8<'YFG<N/<UM\-NZA,Q\)1Z"
M0B$/]$8SZ$8E5"M*^]LT1!P#)F^(,O$-OJ<&W<135PJWL\_*M_5]?T4_7 /$
M%@(0%@+V[>(*@'J 7M[>(' O81+V\1$.>8ID[G,4H <Y/ 3?B)0\A*41^_B4
M3&$I?L7R-X@'D;O(W(^[*N0Y?),UF+J /)0HF<6>4V+U+&LY]Q%RLC S3S%5
M<[%"5L5^F>'6!7-<%Z:UUR6YBX/;1N)HX%\-B@S^WSN@'P\=14MZE>_6.O8;
ML7POLL7=4ID&??\ *T2<-,Z!L;!KJ,:M[YTC1KJ,=6*3SC5<B)8)R/L\ZCGF
M7*;09V\0="R37)FZ.(*MW$E<9.Y-@WNU>F956$733<C]0KYTDV"B3EX\8Y2:
MCV.S]1KJTK]0*ET"]TS537? <CA?%=VOE7D*DYRU:+ K86K]Y"QTD=07<<@%
MLMD@X.S4%2(CV560G$V,U+K1;21/2'3/).N.PW4-RK?Y>C3%9VQV!CLJ8\85
MI],/Y:*KS-.U@=I<FLK 13%E+^I.M!3;Q3R;:?L5SB]*8J0&DQ33(D4I$R%(
M0H 4I2@!2E*   %*4.Q2E  ]BE "A^ !S/E7.L%5W59A9 OV-3B&'QFQR&-4
MVT/IGQO&I:DHQIH+)>G\==V2ZR>DRL( UJZ(V#EW6/&^';+*F4&QJ$G+S>2Z
MO($X99H!=BV&YIVL^':GVR@\^#<O14@:(/DC!96R2,+BJ=U%<!XAP)U/W6WV
MY&MKC8/2'83%4%3[;965'FLA(82R_5(F$K\1/S<+$*D>,T7T55F!$%B*$+(Q
M$]8/I2#V7@ACG?LUE;Z.;(;M82BNG1TYL7K8<Q;,(9#S9MED3%>1Z(RI,O7'
M32;I\9B9-:;B0<7HDHS119)6F-='4D'/U1O!# 0$E).[5ITR*%$IR@8I@$IB
MF ! Q1#L)3 /<#%$/N4P"4?Q >>*2"*!?!%)-(G<1 B9"ID 1^X@0@%* C^(
M@'<?Q$>)X]T[)857.?4UST:''HXU4>CE.E2P?IK0=.I<M<=K)"+.E3I&*%LC
M331<2*[K>?8(60WOGMVH->S<1<S5YUW<G?M5V\=HV=>;3'+M6:M?;<V?@H6;
M2Y<:YSV6EPUJT7%B0^L"O6S:WF@73IU;;1..;=D/&NJ&T WC,+>C1;F<GX.K
MRZ=2,E+A&,TE5_D/"NRC/Z@N5&/0F%X9B_=-"2B;E..+JB=0&L;Y%T_KVL>/
M\S6;"E VQP];,AY@G,97.H4_].)"2/$4VA1*4U'-G<O+-HE:W3TV\*U!A&)L
MF1$'*Y'*RY;A8@!O8?\ D(@/\P$!_>'X_CSP3122*4B9"ID+_5(F )D* B(B
M!2D\2E 1'N(%  $?<0$??FCC7<3/PD<;.WQC]5U.)CJHR+GZRRE5FKK6+=IL
M7* T+)/MU7WK1TK*KE=0?($6*MGXA\[-_@MW8?O16Y#.=G<C+,;I5/TI=NQ#
M\M=9*IJW"N(A->PJH@+23K.9/J4HL(]RB8JNMG1[7D+I?[55VEP<G9)XM?I\
M^G#0S![)RCF,JN4J;9)Y9FPCVSIVZ-'P<9(22R:2)A!JS75'L5,1YV?TQ-BJ
M#L3IYB=W0V=R8AB:HX_PI;F]TJ,M4'A+M1,:T<D^$4VEB$4EH0IWZ)6,VU S
M)Z8JQ43"9%0 D)$.X=A_Y"(#_,.PA^\. #M]N_\ $1'_ #$>-3^X5'P\.*NS
MY-E;?M[U+2"W\?Q'?HYU"Y6?3FL<6!->97-+1LHE)DWV!T$/HY8PC#E!<C5=
M@1=B5\:U0*M!_*-2W<N5K"K4."4$)W6BU<I<+1@/!+F)DJVO0[Q;)Y!Z>6[>
M)I9*1K*N3MCMF:01W*1KYBJT;77%]/K195-N[0;K+-VYGYU@52*8BGH*)D,)
MRF*'4N@?4HQSTRM93:2;NT#,&-LZ:ZV/(,/78*$Q99K-&9;KT[9Y>XUZ0I5D
MC2'@W*LN\G'3)C(23N,@'<<M!RB,NJ#F0286I #M^?Y^XB/^8C_+[<]*C9NJ
M8AE44E#)CY)F.0AQ3,(@(BF)@$4Q$2E$13$HB8 ,(]P 0=5WN)2V;G*(WN/-
MN8_)=C-WYSZ.S^GW<[3S*UJDEB-)F7>6U#JEVTBTEN=Y."4:6UV*]C;57@MS
M*J\?_1=T*FI@YE['^[;RONU;V?H6:]MRW4!T*IJ:JQ50VNU5WP)"8N6Y;)$8
MT=&,P[U9TU"O^:LYXZI.-LRWI]D2?URQG)UF8K*$/3BP11Q07*#1_8U9M5S-
MV,JJTFHN%5D%*R9E("QC%7Q/2K_VW/G2DSC0)MMU+M,+1@??6-6M,9DROX.P
M9D['UEF[PVD)$[">I$K7'[R#EWLPV/''!UDE[)(+S@.G3IW)U]5G(.KF@  !
MV#_W_F(^XB/XB/N(^X\])VK=10BIT$CJI]O34.F0RB?8>X>FH8HG3 !'N $,
M4 'W#L/OSFQ.=T<C2U[Z\*WF??O)NY\\2Y#:XS>R%(^<8S%WIJ:D6\QRVK^T
ME];YVOKK>-E1$T6=&OPRWIT<NF>S7O32INJ7?[DQ*V_5TF/E)'H'4FS0FK?4
M2V17:E\J6IY)))@(2-3C1[7WK)HZL8E+3<AW3'E,4861U3:;E.SLX^^0=1>7
M6R.ZNC.Q]A(>7CP<P2\>^BV#HK<K*&=1S5JS8LTF[)!RV;XE_(/Y=_YB/N(_
MF(^X\<ST>YVAH:%Z_/&^'+F[<LVY66!7>839>;I GL*#<0^WK+3B#9,>Y1YF
M>M%+MQ1ITZE3^X.5%%6M7K^P;3D@7P*6KV!(#(*$O29%0S(K@O2)F(_/!OL'
M^\3_ ,9>0B=)3_M#]7#_ +]LO_Z9'CCB7QW_ ,)]PO\ [9Q__P#I\SI4WO\
MQ/P?_P"MW/\ ]':ZF]XXXXR.GCTXXXX='3CCCAT=....'1TXXXX='3CCCAT=
M....'1TXXXX='3CCCAT=....'1TXXXX='3CCCAT=....'1TXXXX='3CCCAT=
<....'1TXXXX='3CCCAT=?__9              $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
